What Happened?
Redwood City, -based Adverum Promoted Peter Soparkar as Chief Operating Officer
About the Company
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.
About the Person
Peter Soparkar is Chief Operating Officer at Adverum. Previously, Peter held various senior legal leadership roles in the industry.
Info Source
News
Short Profile